Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Form 483
Manufacturing
FDA slams 3 Indian drugmakers in flurry of recent Form 483s
The FDA hit three Indian drugmakers with Form 483s after inspections uncovered unsanitary conditions, broken equipment and poor recordkeeping.
Joseph Keenan
Apr 16, 2024 8:45am
Geopolitical tensions, Carvykti, Enhertu—Fierce Pharma Asia
Apr 12, 2024 8:20am
Jubilant Generics, Contract Pharmaceuticals hit with Form 483s
Apr 9, 2024 8:22am
After a pause, Aurobindo resumes drug shipments from India plant
Mar 13, 2024 3:40pm
Aurobindo's Eugia has received another FDA Form 483
Mar 4, 2024 10:34am
FDA slams Chinese API maker Sichuan Deebio with warning letter
Feb 22, 2024 9:10am